NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS) (Pluristem) announced today a licensing agreement and stock swap with Stem Cell Innovations, Inc. (OTCBB:SCLL) (Stem Cell) for certain marketing rights of Pluristem’s PLX I product in Asia, excluding Japan and 3-D stem cell expansion capability.
